$DRUG News

Bright Minds Biosciences to Present at Upcoming Conferences

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

HC Wainwright & Co. Maintains Buy on Bright Minds Biosciences, Raises Price Target to $145

Bright Minds Biosciences to Present at Upcoming Conferences

Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials

Canadian Securities Exchange Reports January 2026 Performance Figures

BTIG Maintains Buy on Bright Minds Biosciences, Maintains $147 Price Target